Reverse Merger - Summary of Final Purchase Price Allocation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] $ in Thousands	Aug. 01, 2017 USD ($)
Business Acquisition [Line Items]
Cash, cash equivalents and marketable securities	$ 12,376
Prepaid expenses and other assets	518
Intangible assets license agreements	8,610
Accounts payable, accrued expenses and other liabilities	(4,054)
Deferred tax liability	(2,928)
Contingent value rights	(200)
Excess negative goodwill	(1,272)
Total purchase price	$ 13,050